Rosiptor (AQX-1125) is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro.
体外研究
Rosiptor (0.1-10 μM; 30 minutes) inhibits Akt activation in MOLT-4, but not in Jurkat cells.
Western Blot Analysis
Cell Line:
MOLT-4 cells and SHIP1-deficient Jurkat cells (IGF-1 stimulation)
Concentration:
0.1, 1, 10 μM
Incubation Time:
30 minutes
Result:
Induced a concentration-dependent decrease in Akt phosphorylation in MOLT-4 cells, while it failed to affect Akt phosphorylation in Jurkat cells.
体内研究
Rosiptor (3-30 mg/kg; p.o.; daily for 3 days) significantly reduces the total number of BAL leukocytes in NSC-125066-challenged mice and reduces MPO activity.
Rosiptor (10 mg/kg; p.o.) has the Cmax value of 0.830 μM and the t1/2 value of 5.2 hours. AQX-1125 also exhibits >80% oral bioavailability.
Animal Model:
6-8 weeks old male CD-1 mice
Dosage:
3, 10, 30 mg/kg
Administration:
p.o.; daily for 3 days
Result:
Significantly reduced the total number of BAL leukocytes in NSC-125066-challenged mice, up to a maximum of 60% at 7 days and 63% at 21 days at 30 mg/kg; Reduced MPO activity by 54% at Day 7 and by 74% at Day 21 at 30 mg/kg.
Animal Model:
Male Sprague-Dawley rats
Dosage:
10 mg/kg (Pharmacokinetic Study)
Administration:
Oral administration
Result:
The Cmax value is 0.830 μM and the t1/2 value is 5.2 hours.
分子式
C20H35NO2
分子量
321.50
CAS号
782487-28-9
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
-20°C
1 month
溶解性数据
In Vitro:
DMSO : 150 mg/mL (466.56 mM; Need ultrasonic and warming)